These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21832002)

  • 1. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
    Tiefenthaler M; Hohla F; Irschick E; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
    Immunobiology; 2003; 207(2):149-57. PubMed ID: 12675273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.
    Hodge LS; Taub ME; Tracy TS
    Biochem Pharmacol; 2011 Apr; 81(7):950-6. PubMed ID: 21291869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
    Veltkamp SA; Pluim D; van Eijndhoven MA; Bolijn MJ; Ong FH; Govindarajan R; Unadkat JD; Beijnen JH; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2415-25. PubMed ID: 18723487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
    Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
    Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
    Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
    Yilmaz B; Kadioğlu YY; Aksoy Y
    Anal Biochem; 2004 Sep; 332(2):234-7. PubMed ID: 15325290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
    Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS.
    Honeywell RJ; Giovannetti E; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1203-13. PubMed ID: 22132976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
    Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
    Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
    Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
    Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
    Honeywell RJ; Ruiz van Haperen VW; Veerman G; Smid K; Peters GJ
    Int J Biochem Cell Biol; 2015 Mar; 60():73-81. PubMed ID: 25562513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.
    Bapiro TE; Richards FM; Goldgraben MA; Olive KP; Madhu B; Frese KK; Cook N; Jacobetz MA; Smith DM; Tuveson DA; Griffiths JR; Jodrell DI
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1243-53. PubMed ID: 21431415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM; Gagnon J; Primeau M; Momparler RL
    Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
    Freise KJ; Martín-Jiménez T
    J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.
    Sigmond J; Honeywell RJ; Postma TJ; Dirven CM; de Lange SM; van der Born K; Laan AC; Baayen JC; Van Groeningen CJ; Bergman AM; Giaccone G; Peters GJ
    Ann Oncol; 2009 Jan; 20(1):182-7. PubMed ID: 18701427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.